TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2504629

Group type: EXPERIMENTAL
Intervention: Mepartricin 150,000 IU/day for 30 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 7585

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 31476522

Group type: EXPERIMENTAL
Intervention: Tongue stretching exercises (TSE), performed five times a week for four weeks, consisting of dynamic and static passive stretching exercises (20 repetitions each)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 25
Study: 28692630

Group type: EXPERIMENTAL
Intervention: Strength training (n = 10; 7 females, 3 males)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (n = 11; 2 females, 9 males)
Number of subjects: 21
Study: 25712312

Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg once daily
Number of subjects: 500
Study: 24277815

Group type: EXPERIMENTAL
Intervention: Sex hormone binding globulin
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Progesterone (in early group)
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Endogenous sex steroid levels
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Hormone concentrations
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Temporal proximity to menopause
Number of subjects: 643
Study: 21755316

Group type: EXPERIMENTAL
Intervention: Polyester mesh
Number of subjects: 78

Group type: COMPARATOR
Intervention: Polypropylene mesh
Number of subjects: 78
Study: 19565542

Group type: EXPERIMENTAL
Intervention: T-614 50 mg/day for 24 weeks
Number of subjects: 489

Group type: COMPARATOR
Intervention: Methotrexate (MTX) 10 mg/week for 4 weeks and 15 mg/week for 20 weeks
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: T-614 25 mg/day for 4 weeks and 50 mg/day for 20 weeks
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: All groups (T-614 and MTX)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: T-614 therapy groups
Number of subjects: 489
Study: 16397282

Group type: EXPERIMENTAL
Intervention: Otamixaban (various intravenous doses)
Number of subjects: 0
Study: 15037526

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg BID)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low-dose aspirin (100 mg/d)
Number of subjects: 9
Study: 11109976

Group type: EXPERIMENTAL
Intervention: Combined oral contraception (ethinylestradiol plus desogestrel) for 21 days each month for 12 months
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Combined oral contraception (ethinylestradiol plus desogestrel) plus spironolactone daily for 12 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 43
Study: 9079166

Group type: EXPERIMENTAL
Intervention: Prophylactic adhesive athletic tape
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Non-adhesive prewrap (underwrap)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 40 minutes of vigorous exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: No external ankle support
Number of subjects: 20
Study: 8371916

Group type: EXPERIMENTAL
Intervention: PhXA41 (0.006% concentration, 60 micrograms/ml) administered once daily
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PhXA41 (0.006% concentration, 60 micrograms/ml) administered twice daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PhXA41 (both dosing regimens)
Number of subjects: 50
Study: 29445188

Group type: EXPERIMENTAL
Intervention: Circadian misalignment (night shifts)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Circadian alignment (day shifts)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circadian misalignment
Number of subjects: 0
Study: 26562929

Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no hyperventilation)
Number of subjects: 10
Study: 24736769

Group type: EXPERIMENTAL
Intervention: Midstance to Midstance Running (MMR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 18
Study: 23044231

Group type: EXPERIMENTAL
Intervention: UC‐MSC transplantation
Number of subjects: 54
Study: 20392866

Group type: EXPERIMENTAL
Intervention: Pioglitazone for 10 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Metformin for 10 weeks
Number of subjects: 86
Study: 18263770

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 0
Study: 15948994

Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 972

Group type: COMPARATOR
Intervention: Corticosteroid ointment regimen
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 972
Study: 12868009

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1 g/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 10561192

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) alone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) alone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sequential interleukin-3 (IL-3) and GM-CSF
Number of subjects: 48
Study: 8696542

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 154

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 154
Study: 1908478

Group type: EXPERIMENTAL
Intervention: hMG alone (Group II)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: hMG plus GnRH agonists (Group III)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Normal cycles (Group I)
Number of subjects: 68
Study: 6347316

Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy (HSV)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Truncal vagotomy and pyloroplasty (TVP)
Number of subjects: 137
Study: 31473553

Group type: EXPERIMENTAL
Intervention: Women in editorial leadership positions (Editor-in-chief/deputies, Associate/section editors)
Number of subjects: 8423

Group type: COMPARATOR
Intervention: Men (M.D. psychiatrists)
Number of subjects: 8423

Group type: COMPARATOR
Intervention: Women (Ph.D. psychologists)
Number of subjects: 8423

Group type: EXPERIMENTAL
Intervention: Women in editorial leadership positions
Number of subjects: 8423

Group type: EXPERIMENTAL
Intervention: Editorial board positions
Number of subjects: 8423
Study: 30118808

Group type: EXPERIMENTAL
Intervention: Sodium nitrate (NaNO3) supplementation for eight weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 21
Study: 26869087

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHA/EPA supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iron + DHA/EPA combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Iron alone)
Number of subjects: 0
Study: 23111536

Group type: EXPERIMENTAL
Intervention: Long-term secondary prevention programme with one further rehabilitation session after 6 months and regular telephone reminders over 36 months
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 600
Study: 22286978

Group type: EXPERIMENTAL
Intervention: Cefaclor formulation 1 (250 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cefaclor formulation 2 (250 mg)
Number of subjects: 20
Study: 20418301

Group type: EXPERIMENTAL
Intervention: Gabapentin (15 mg/kg preoperatively, 5 mg/kg 3 times per day for 5 days postoperatively)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 17554473

Group type: EXPERIMENTAL
Intervention: 1 ml paté
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 ml egg white
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 ml omelette
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 ml radiolabeled omelette
Number of subjects: 30
Study: 16096040

Group type: EXPERIMENTAL
Intervention: Flock-of-Birds electromagnetic tracking system for asymptomatic subjects
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flock-of-Birds electromagnetic tracking system for symptomatic subjects
Number of subjects: 60
Study: 12510544

Group type: EXPERIMENTAL
Intervention: Prostanoids (including prostaglandin E1)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Prostacyclin and its analogues
Number of subjects: 557
Study: 9834957

Group type: EXPERIMENTAL
Intervention: Slow‐dissolving formulation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Medium‐dissolving formulation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Fast‐dissolving formulation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inderal 80 mg
Number of subjects: 13
Study: 7657848

Group type: EXPERIMENTAL
Intervention: Isradipine (1.25 mg twice daily)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Enalapril (2.5 mg twice daily)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Isradipine non-responders
Number of subjects: 160

Group type: COMPARATOR
Intervention: Enalapril non-responders
Number of subjects: 160
Study: 2750531

Group type: EXPERIMENTAL
Intervention: 15 U/m2/week of GH by daily subcutaneous injections for a mean of 0.82 years
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 30 U/m2/week of GH by daily subcutaneous injections for a mean of 0.92 years
Number of subjects: 31
Study: 789083

Group type: EXPERIMENTAL
Intervention: Lithium treatment (adjusted every two weeks to maintain serum level between 0.7 and 1.0 mmol/1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31691849

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 120
Study: 31547761

Group type: EXPERIMENTAL
Intervention: Acute tryptophan interventions (depletion, loading, balanced)
Number of subjects: 611

Group type: COMPARATOR
Intervention: 5-HTTLPR genotype
Number of subjects: 611
Study: 28846009

Group type: EXPERIMENTAL
Intervention: 1000 mg omega‐3 fatty acids plus 400 mg vitamin E
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 26324672

Group type: EXPERIMENTAL
Intervention: ARB therapy (telmisartan)
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Non-ARB standard therapy
Number of subjects: 1228
Study: 25168268

Group type: EXPERIMENTAL
Intervention: 60 mg tabalumab Q4W
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: 60/120 mg tabalumab Q4W
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: 60/120/60 mg tabalumab Q4W
Number of subjects: 182
Study: 22361261

Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg three times daily for 6 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 20503799

Group type: EXPERIMENTAL
Intervention: Amplified sound samples (mild gain, moderate gain)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Unamplified sound samples
Number of subjects: 48
Study: 17213240

Group type: EXPERIMENTAL
Intervention: Pre-emptive swallowing stimulation (duration of stimulation: 7.39±3.6 days)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no stimulation)
Number of subjects: 33
Study: 16288342

Group type: EXPERIMENTAL
Intervention: CP and iodoform
Number of subjects: 245

Group type: COMPARATOR
Intervention: CP alone
Number of subjects: 245
Study: 12356283

Group type: EXPERIMENTAL
Intervention: Desmopressin (0.396 microg administered intravenously as a bolus injection)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lithium treatment (period preceding the 6th study day)
Number of subjects: 8
Study: 10197827

Group type: EXPERIMENTAL
Intervention: Methylphenidate therapy
Number of subjects: 34
Study: 7758212

Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: CAPD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 0
Study: 2317466

Group type: EXPERIMENTAL
Intervention: Social support intervention in pregnancy in addition to standard antenatal care
Number of subjects: 509

Group type: COMPARATOR
Intervention: Standard antenatal care only
Number of subjects: 509
Study: 7191299

Group type: EXPERIMENTAL
Intervention: Bay g 5421 (acarbose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30907429

Group type: EXPERIMENTAL
Intervention: Ipsi-lesional cerebellar rTMS (10 Hz, 250 pulses)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Contra-lesional cerebellar rTMS (10 Hz, 250 pulses)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham cerebellar rTMS
Number of subjects: 30
Study: 28513245

Group type: EXPERIMENTAL
Intervention: Sit-stand workstation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Seated desk
Number of subjects: 25
Study: 26360086

Group type: EXPERIMENTAL
Intervention: Collaborative-care depression care management (DCM) intervention
Number of subjects: 326

Group type: COMPARATOR
Intervention: Enhanced care as usual
Number of subjects: 326
Study: 23572075

Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg/d, twice daily for 28 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (twice daily for 28 days)
Number of subjects: 40
Study: 21980828

Group type: EXPERIMENTAL
Intervention: Suplatast tosilate (100 mg orally 3 times a day for 2 years)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fluticasone (100 pg inhaled twice a day for 2 years)
Number of subjects: 32
Study: 19212170

Group type: EXPERIMENTAL
Intervention: Preoperative TACE
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no preoperative treatment)
Number of subjects: 108
Study: 16881779

Group type: EXPERIMENTAL
Intervention: Passage meditation intervention (8-week, 2-hr per week training)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Passage meditation intervention
Number of subjects: 58
Study: 14604604

Group type: EXPERIMENTAL
Intervention: CFS patients
Number of subjects: 20
Study: 10341400

Group type: EXPERIMENTAL
Intervention: Nuchal translucency measurements in fetuses affected by homozygous alpha-thalassemia-1
Number of subjects: 94

Group type: COMPARATOR
Intervention: Nuchal translucency measurements in controls from the general obstetric population
Number of subjects: 94
Study: 8983437

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (DSCG) at concentrations of 10(‐7) ‐ 10(‐9M)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (Healthy Subjects)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (Seasonal Asthmatic)
Number of subjects: 20
Study: 1827967

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 30
Study: 7034617

Group type: EXPERIMENTAL
Intervention: 0.5% Norepinephrine dipivalylate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31907017

Group type: EXPERIMENTAL
Intervention: Implementation of Infant Pain Practice Change (ImPaC) Resource for six months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard practice (SP)
Number of subjects: 18
Study: 30551157

Group type: EXPERIMENTAL
Intervention: ER + IVRE
Number of subjects: 85

Group type: COMPARATOR
Intervention: ER + RP
Number of subjects: 85
Study: 27893087

Group type: EXPERIMENTAL
Intervention: Collaborative care plus 2 years of home‐based occupational therapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Collaborative care alone (Control)
Number of subjects: 180
Study: 25381032

Group type: EXPERIMENTAL
Intervention: Calcitriol (1,25 OH2D3) supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D3 supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22823871

Group type: EXPERIMENTAL
Intervention: α(1)-blockade (prazosin, 1 mg/20 kg body weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 20595648

Group type: EXPERIMENTAL
Intervention: Milled flaxseed (FXS, n = 13; 32 g/d)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FXO, n = 12; 13 g/d)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (CTL, n = 9; no flax)
Number of subjects: 34
Study: 17592102

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (2 mg/d)
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/d)
Number of subjects: 630
Study: 16096436

Group type: EXPERIMENTAL
Intervention: Bendmustine, methotrexate and 5-fluorouracil (BMF)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: BMF
Number of subjects: 364

Group type: COMPARATOR
Intervention: BMF and CMF
Number of subjects: 364
Study: 12149202

Group type: EXPERIMENTAL
Intervention: ADE (cytarabine 100 mg/m(2)/d by 7‐day infusion, daunorubicin 60 mg/m(2) and etoposide 100 mg/m(2) daily for 3 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: ADEP (daunorubicin 40 mg/m(2) and etoposide 60 mg/m(2) for 3 days with PSC‐833, 2.8 mg/kg over 2 hours, and then 10 mg/kg/d by 3‐day infusion)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ADE (for patients with PSC‐833‐modulated dye efflux)
Number of subjects: 120

Group type: COMPARATOR
Intervention: ADEP (for patients with PSC‐833‐modulated dye efflux)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 120
Study: 10084159

Group type: EXPERIMENTAL
Intervention: HPMC-10 (10% hydroxypropyl methylcellulose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Tegretol CR 200 (commercially available controlled-release carbamazepine preparation)
Number of subjects: 8
Study: 7668855

Group type: EXPERIMENTAL
Intervention: Predictive model for fall risk assessment
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Cross-validation of predictive model
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Risk factor model including seven risk factors
Number of subjects: 338
Study: 2111251

Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac potassium three times daily for 7 days
Number of subjects: 93

Group type: COMPARATOR
Intervention: 20 mg/day piroxicam for 7 days
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 93
Study: 6963332

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA), 600 mg, p.o., twice daily for 2 years
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 66
Study: 30688523

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with 5‐fluorouracil and oxaliplatin (FOLFOX)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiation
Number of subjects: 1000
Study: 29138273

Group type: EXPERIMENTAL
Intervention: Intensive treatment (INT) of type 1 diabetes
Number of subjects: 1213

Group type: COMPARATOR
Intervention: Conventional treatment (CONV)
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: Intensive treatment (INT)
Number of subjects: 1213
Study: 27103060

Group type: EXPERIMENTAL
Intervention: Modelling strategy
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Reward strategy
Number of subjects: 204

Group type: COMPARATOR
Intervention: Neutral instructions
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Verbal encouragement (for children low in Reward Sensitivity)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Immediate reward (for children high in Reward Sensitivity)
Number of subjects: 204
Study: 25938131

Group type: EXPERIMENTAL
Intervention: Topical sodium nitrite 0.5% cream
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Topical sodium nitrite 1.0% cream
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Topical sodium nitrite 1.5% cream
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Topical sodium nitrite 1.8% cream
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Topical sodium nitrite 2.0% cream
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Post-hoc analysis of pain
Number of subjects: 18
Study: 21967073

Group type: EXPERIMENTAL
Intervention: Individual virtual reality exposure therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outcome expectancy
Number of subjects: 0
Study: 18940275

Group type: EXPERIMENTAL
Intervention: Age at menarche
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Weight concerns
Number of subjects: 71
Study: 17502577

Group type: EXPERIMENTAL
Intervention: Otamixaban (highest dose)
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: Otamixaban (doses 1 to 5)
Number of subjects: 947

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 947
Study: 17290435

Group type: EXPERIMENTAL
Intervention: Exposure to approximately 1600 mT (twice)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Exposure to approximately 800 mT
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Negligible static field exposure
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Standardized head movements generating approximately 300 and approximately 150 mT.s(‐1) r.m.s.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Stable head position (control session)
Number of subjects: 27
Study: 14981398

Group type: EXPERIMENTAL
Intervention: Combination with protease inhibitor (PI) early
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: Combination without protease inhibitor (PI)
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: Monotherapy (monoRx) early
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: Monotherapy (monoRx) late
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: Combination without protease inhibitor (PI) late
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: Combination with protease inhibitor (PI) late
Number of subjects: 1407